In this corpus, a transgene-free edited line is a genome-edited plant or animal in which no foreign DNA remains after the editing and breeding process, typically achieved by segregating out the editing machinery through subsequent generations or by using transient delivery methods. Patent claims in this space cover both the editing and segregation strategy itself and, just as often, the screening or detection method used to prove the transgene is absent. That detection layer matters commercially because many regulators classify a line differently depending on whether transgene absence can be demonstrated, so the assay claims can be as commercially significant as the editing claims.

The assignee ranking behind this landscape covers 100 companies, with the leading filer holding 68 records against a total of 1,633 records in scope. The top 10 assignees combined account for only 18.3% of all records, which means the field has one clearly dominant filer at the top but a long tail below it rather than a small cartel of controlling portfolios. Practical due diligence should check both the leading names and the broader ranked set, since a mid-ranked assignee can still hold a blocking claim in a specific sub-area.

G01N (material analysis and testing) and C12Q (enzyme and DNA-based measuring) together cover more of the 1,633 records than A01H, the plant-breeding classification itself, at 21.9% and 19.2% of records respectively against 10.2% for A01H. This reflects the fact that proving a line is transgene-free is itself a patentable technical problem, requiring PCR, sequencing or other molecular assays capable of detecting trace foreign DNA at very low levels. A company developing an edited line therefore needs freedom-to-operate coverage on the verification assay, not just on the editing method.

Filings peaked at 83 in 2018 and have since settled lower, with 2021 to 2024 moving from 67 to 62 records, a -7% change over that span. That is a modest plateau rather than a collapse, and the years since 2024 should not be read as a further decline because patent publication typically lags filing by around 18 months, meaning recent-year counts are still incomplete. A fair read of the trend is that the field has matured past its early filing surge but remains active.

Relative to the corpus's dense detection and breeding classifications, sub-areas such as multi-edit stacking verification, breeding-cycle acceleration methods, and regulatory-classification documentation tools show comparatively thin coverage. These are technically specific niches rather than broad claim territory, so a first mover would need a precisely scoped claim rather than a broad method claim to establish position. Given how concentrated citation activity is among older, more general records, a newer filing that targets one of these narrower branches has a better chance of clearing prior art cleanly.